Exelixis, Inc. (EXEL)
Company Info
| ISIN | US30161Q1040 |
|---|---|
| CUSIP | 30161Q104 |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | Apr 7, 2000 |
Highlights
| Market Cap | $10.24B |
|---|---|
| EPS (TTM) | $1.55 |
| PE Ratio | 23.13 |
| PEG Ratio | 2.63 |
| Total Revenue (TTM) | $2.02B |
| Gross Profit (TTM) | $1.94B |
| EBITDA (TTM) | $609.58M |
| Year Range | $19.20 - $36.60 |
| Target Price | $32.35 |
| Short % | 4.70% |
| Short Ratio | 5.04 |
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Popular comparisons: EXEL vs. VOO, EXEL vs. VRTX, EXEL vs. SCHD, EXEL vs. SPY, EXEL vs. QQQ, EXEL vs. AAPL
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Exelixis, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Exelixis, Inc. had a return of 46.69% year-to-date (YTD) and 64.67% in the last 12 months. Over the past 10 years, Exelixis, Inc. had an annualized return of 35.24%, outperforming the S&P 500 benchmark which had an annualized return of 11.39%.
| Period | Return | Benchmark |
|---|---|---|
| Year-To-Date | 46.69% | 25.48% |
| 1 month | 34.11% | 2.14% |
| 6 months | 66.62% | 12.76% |
| 1 year | 64.67% | 33.14% |
| 5 years (annualized) | 16.40% | 13.96% |
| 10 years (annualized) | 35.24% | 11.39% |
Monthly Returns
The table below presents the monthly returns of EXEL, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | -9.30% | 0.64% | 8.36% | -1.14% | -7.54% | 3.60% | 4.36% | 11.00% | -0.31% | 27.94% | 46.69% | ||
| 2023 | 9.85% | -3.06% | 13.64% | -5.72% | 5.36% | -0.88% | 3.14% | 13.60% | -2.41% | -5.77% | 5.93% | 10.00% | 49.56% |
| 2022 | -0.98% | 13.43% | 10.42% | -1.46% | -17.95% | 13.58% | 0.48% | -15.20% | -11.61% | 5.74% | 3.02% | -6.09% | -12.25% |
| 2021 | 10.66% | -2.48% | 4.29% | 8.99% | -8.41% | -19.20% | -7.52% | 13.77% | 10.28% | 1.75% | -21.94% | 8.87% | -8.92% |
| 2020 | -2.38% | 8.08% | -7.37% | 43.41% | 0.06% | -3.93% | -2.74% | -3.77% | 10.04% | -16.24% | -6.45% | 4.75% | 13.90% |
| 2019 | 19.83% | -5.01% | 6.30% | -17.39% | -0.36% | 9.09% | -0.47% | -6.68% | -10.91% | -12.64% | 7.64% | 5.95% | -10.42% |
| 2018 | -0.30% | -14.88% | -14.15% | -6.00% | -0.43% | 3.81% | -3.81% | -9.23% | -5.69% | -21.73% | 46.43% | -3.15% | -35.30% |
| 2017 | 21.53% | 18.82% | 0.65% | 3.37% | -16.47% | 31.64% | 10.07% | 7.86% | -17.13% | 2.31% | 9.24% | 12.26% | 103.89% |
| 2016 | -18.09% | -21.21% | 9.89% | 15.25% | 40.78% | 20.34% | 17.54% | 21.46% | 14.71% | -17.20% | 59.77% | -11.88% | 164.36% |
| 2015 | 29.86% | 56.68% | -12.29% | 0.00% | 22.57% | 19.37% | 52.39% | 3.84% | -5.71% | 7.31% | -4.98% | -1.40% | 291.67% |
| 2014 | 12.23% | 2.62% | -49.86% | 0.00% | -6.50% | 2.42% | 18.88% | 2.73% | -63.04% | 11.11% | -2.35% | -13.25% | -76.51% |
| 2013 | 1.97% | -2.15% | 1.32% | 12.34% | -6.74% | -6.20% | 11.45% | -0.99% | 16.17% | -15.29% | 18.26% | 5.15% | 34.14% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current risk-adjusted rank of EXEL is 87, placing it in the top 13% of stocks on our website in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Exelixis, Inc. (EXEL) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the Exelixis, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Exelixis, Inc. was 97.38%, occurring on Dec 24, 2014. The portfolio has not yet recovered.
The current Exelixis, Inc. drawdown is 28.55%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -97.38% | Jul 27, 2000 | 3626 | Dec 24, 2014 | — | — | — |
| -38.22% | May 8, 2000 | 12 | May 23, 2000 | 8 | Jun 5, 2000 | 20 |
| -9.04% | Jun 23, 2000 | 2 | Jun 26, 2000 | 2 | Jun 28, 2000 | 4 |
| -8.99% | Jul 13, 2000 | 2 | Jul 14, 2000 | 6 | Jul 24, 2000 | 8 |
| -8.48% | Jun 8, 2000 | 7 | Jun 16, 2000 | 3 | Jun 21, 2000 | 10 |
Volatility
Volatility Chart
The current Exelixis, Inc. volatility is 13.50%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
Valuation
The Valuation section provides an assessment of the market value of Exelixis, Inc. compared to its peers in the Biotechnology industry.
PE Ratio
The chart displays the price to earnings (P/E) ratio for EXEL in comparison to other companies of the Biotechnology industry. Currently, EXEL has a PE value of 23.1. This PE ratio falls in the average range for the industry.PEG Ratio
The chart displays the price to earnings to growth (PEG) ratio for EXEL in comparison to other companies of the Biotechnology industry. Currently, EXEL has a PEG value of 2.6. This PEG ratio is much higher than those of other companies of the industry. This might be an indicator of the company being overvalued.Historical P/E Ratio Chart
The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Exelixis, Inc..
Loading data...
Income Statement
| TTM | |
|---|---|
| Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
| Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
| Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |